Title Page

Title

Prediction Model for Severe Community-acquired Pneumonia Development
among Patients with Diabetes Mellitus

Authors

Ruoming TAN^{1¶} MD; Tingting PAN^{1¶} MD; Yuzhen QIU^{1¶} MD; Jiahui WANG¹
MD; Xiaoling QI¹ MD; Erzhen CHEN² MD, PhD; Min ZHOU³ MD, PhD; Jialin
LIU^{1*} MD, PhD; Hongping QU^{1*} MD, PhD;

¶These authors contributed equally to this work.

Affiliations

1 Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong
University School of Medicine, Shanghai, China

2 Department of Emergency, Ruijin Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai, China

3 Department of Respiratory and Critical Care, Ruijin Hospital, Shanghai
Jiaotong University School of Medicine, Shanghai, China

*** Corresponding author**

Hongping QU, MD, PhD

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Address: 197 Rui-Jin Er Rd, Shanghai 200025, China

Tel: 86-021-64370045 Ext. 670507

E-mail: hongpingqu0412@hotmail.com

Jialin LIU , MD, PhD

Address: 197 Rui-Jin Er Rd, Shanghai 200025, China

Tel: 86-021-64370045 Ext. 670507

E-mail: lj111243@rjh.com.cn

Abstract

Introduction: Diabetes is an independent risk factor for the development of severe community-acquired pneumonia (CAP) and associated with pneumonia-related hospitalization as well as mortality. Here, we assessed several selected biomarkers to determine their predictive value for progression to severe CAP among diabetic patients.

Research design and methods: A retrospective cohort study of diabetic patients with CAP was conducted at a tertiary teaching hospital. The prediction model group (N=100) comprised patients registered between January 2015 to December 2016. Multivariate analysis was performed to identify predictive biomarkers from this cohort. The validation group (N=108) comprised the patients between January 2017 to February 2019. Predictive performance was assessed in the validation group.

Results: A total of 208 diabetic inpatients with CAP were recruited. Further multivariate analysis showed that C-reactive protein (CRP), absolute lymphocyte count (ALC), immunoglobulin (IgM), and HbA1C at admission were independently associated with progression to severe CAP in diabetic patients during hospitalization. The prediction model
$$=0.0179555*CRP+1.975918* HbA1C-2.879364* ALC -0.026255* IgM -$$

8.220555. The area under ROC (AUROC) curve in the validation group was 0.851 (0.781–0.921) with statistical significance ($P < .05$).

Conclusions: In diabetic patients with CAP, a combination of CRP, ALC, IgM, and HbA1C at admission could be used to predict the progression to severe CAP.

Keywords: prediction, severe community-acquired pneumonia, diabetes mellitus, multivariate analysis

Significance of this study

What is already known about this subject?

1. Diabetes is an independent risk factor for the development of severe community-acquired pneumonia (CAP) and associated with pneumonia-related hospitalization as well as mortality.
2. It is essential to identify these patients early and prevent them from progressing to SCAP to improve clinical outcomes.

What are the new findings?

1. C-reactive protein (CRP), absolute lymphocyte count (ALC), immunoglobulin (IgM), and HbA1C at admission were independently associated with progression to severe CAP in diabetic patients during hospitalization.

2. The prediction model $= 0.0179555 * \text{CRP} + 1.975918 * \text{HbA1C} - 2.879364 * \text{ALC} - 0.026255 * \text{IgM} - 8.220555$.
3. The area under ROC (AUROC) curve in the validation group was 0.851 (0.781–0.921) with statistical significance ($P < .05$).

How might these results change the focus of research or clinical practice?

1. In patients with diabetes and CAP, HbA1C, CRP, ALC, IgM at admission, and their combination could be used to predict the progression to severe CAP during hospitalization with good accuracy.
2. Due to the included biomarkers are common, our finding may be performed well in clinical practice and then improve the early management of diabetic patients with CAP.

Introduction

Diabetes mellitus is a common chronic disease with multiple complications and contributes to the global health care burden. It is estimated that in 2011, 366 million patients with diabetes were reported worldwide, and by 2030, the number of patients with diabetes will increase by 50%¹. In addition, in the United States, diabetes is reported as one of the ten leading causes of death.

Infection is one of the severe complications in patients with diabetes, and the incidence varied between 32.7% and 90.5%^{2,3}. The lower respiratory tract is

thought as the most common site involved with infection in diabetic patients ⁴⁻⁶. Due to the immunocompromised state, patients with diabetes appear more susceptible to pneumonia than patients without diabetes. Besides this, these patients have an increased risk of hyperglycemia, impaired lung function, and other chronic complications (such as heart disease, renal failure, and pulmonary microangiopathy) ⁷⁻⁹. In recent studies, it was demonstrated that diabetes is an independent risk factor for the development of severe community-acquired pneumonia (CAP) and associated with pneumonia-related hospitalization as well as mortality ^{8, 10-14}. Hence, based on the above mentioned, to develop a predictive tool for the progression of CAP to severe CAP in patients with diabetes may be useful to improve the management of diabetic patients with CAP.

Unfortunately, limited tools were available for the prediction of severe CAP among diabetic patients with CAP. In the study, the risk factors for severe CAP among patients with CAP were evaluated, then selected variables, and their combination was assessed for predicting the presence of severe CAP among diabetic patients with CAP.

Methods

Design and setting

A retrospective cohort study was conducted at a tertiary teaching hospital between January 2015 to February 2019. The study protocol was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine, China. Informed consent from study patients was not required because of the retrospective design of the cohort study.

Patients selection and definitions

A total of 208 diabetic patients hospitalized with CAP were recruited. We divided the patients according to their year of pneumonia diagnosis. The prediction model group (N=100) comprised patients registered between January 2015 to December 2016, and the validation group (N=108) included the patients between January 2017 to February 2019. The basic characteristics of the two cohorts are listed in Table 1. CAP was defined by the following criteria: 1) acute lower respiratory tract infection with at least two symptoms (e.g., fever, cough or sputum production, dyspnea, chest pain); 2) new focal signs on physical examination of the chest; 3) new infiltrates on chest x-ray¹⁵.

Diabetes mellitus was considered to be present if diagnosed in the past medical history. Severe CAP was diagnosed according to the guidelines issued by Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) and defined if 1) met one of the major criteria: acute respiratory failure requiring invasive mechanical ventilation, septic shock with the need for vasopressors; 2) met at least three minor criteria: respiratory rate ≥ 30 bpm, a

ratio of partial pressure of arterial oxygen to fraction of inspired oxygen ($\text{PaO}_2/\text{FiO}_2$) ≤ 250 , blood urea nitrogen (BUN) ≥ 20 mg/dL, white blood cell count $< 0.4 \times 10^9/\text{L}$, platelet count $< 100 \times 10^9/\text{L}$, body temperature $< 36^\circ\text{C}$, multi-lobar infiltrates, confusion/disorientation, and hypotension requiring aggressive fluid resuscitation ¹⁵.

Exclusion criteria were as follows: age less than 18 years, treatment with polyclonal intravenous immunoglobulins in the previous three months, an immunocompromised condition, or insulin requirement during the hospital stay without a prior history of diabetes. Patients with a lack of cellular and humoral immunity analysis data were also excluded. Immunosuppression was defined as oncology; hematology; human immunodeficiency virus infection; treatment ≥ 20 mg corticosteroids daily for ≥ 14 days; chemotherapy or radiation therapy during the previous six months; immunosuppressive therapy after organ or bone marrow transplantation; and active tuberculosis ¹⁶.

Data collection

We collected data on demographic characteristics, symptoms and vital signs, comorbidities (chronic respiratory disease, heart, kidney, liver, and neurologic disorders), and the details of treatment for each patient during hospitalization, such as mechanical ventilation and renal replacement. Laboratory data of blood cell counting, hepatic, renal, cardiac function test, cellular and humoral

immunity analysis during the first 72 hours after the diagnosis of CAP were recorded.

.Lymphocyte subset and immunoglobulin analysis

Samples of peripheral blood were collected in ethylenediaminetetraacetic acid tubes during the first 72 hours after CAP diagnosis. This measurement was carried out by using the automatic analyzers available at the central laboratory, in accordance with approved standard operative procedures for clinical use.

Statistical analysis

The data are reported as No. (%) or as median (interquartile range [IQR]) for categorical and continuous variables, respectively. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. The Student *t*-test was used to compare the means of continuous variables and the normality of data distribution. Otherwise, the Mann-Whitney U-test was used. Categorical data were tested using the chi-square (χ^2) test. Of the clinical baseline characteristics, only those with *P* values < .05 by univariate analysis were candidates for the multivariate model, which was finally determined with a backward stepwise variable selection procedure. The multivariate logistic regression analyses were summarized by estimating the odds ratios (OR) and respective 95% confidence intervals (CI). To evaluate the predictive value of the combination of new predictors to predict severe CAP occurrence, we constructed a predictive logistic regression model. Predictive performance was

assessed in the evaluation group by estimating negative and positive predictive values, sensitivity and specificity, and the AUC with receiver operating-characteristic (ROC) curves, with corresponding 95% CI. All *P* values were two-sided, with values < 0.05 considered statistically significant. Statistical analyses were performed using Stata 12.0 for Windows (StataCorp, TX, USA).

Results

Patient clinical characteristics data

A total of 208 CAP patients with DM (64 women and 144 men) were included, and the patients were divided into the prediction model group (N=100) registered between January 2015 to December 2016 and the validation group (N=108) between January 2017 to February 2019. The mean age of these patients at admission was 69 years old (95% CI, 57 to 77.75). 109 patients progressed to severe pneumonia, thus classified into severe pneumonia-, and 99 patients into non-severe pneumonia groups. The most common underlying condition for all participants was cardiovascular disease (24%). The mean length of stay of the patients with CAP was 16 days, and 16 (7.7%) died within 28 days after diagnosis. The demographic and clinical characteristics of the prediction model group and the validation group are shown in Table 1.

Table 1 Baseline characteristics of DM patients in prediction model group and validation group.

Variables	Prediction model group (n=100)	Validation group (n=108)	P value
Age, mean $\pm$ sd, (yr)	67.65 $\pm$ 1.36	65.19 $\pm$ 1.48	0.26
>65 yr, (%)	59 (59%)	64 (59.26%)	0.97
Male gender, (n, %)	69 (69)	76 (70.37)	0.83
Smoking, (n, %)	33 (33%)	41 (38.68)	0.40
Drinking, (n, %)	11 (11%)	12 (11.32)	0.94
Fasting plasma glucose (mmol/L)	11.43 $\pm$ 0.86	11.49 $\pm$ 0.47	0.95
HbA1C, (%)	8.08 $\pm$ 0.12	7.90 $\pm$ 0.15	0.37
Chronic diseases, (n, %)			
Chronic respiratory disease	10 (10%)	8 (7.41)	0.51
Congestive heart failure	29 (29%)	21 (19.44)	0.11
Hypertension	69 (69%)	63 (58.33)	0.11
Kidney disease	18 (18%)	17 (15.74)	0.66
History of stroke	23 (23%)	19 (17.59)	0.33
Lab examinations			
C-reactive protein, (mg/L)	41.3 (16.3, 106)	88.75 (37.7, 160)	0.0012
White blood cell, (10^9 /L)	10.17 (7.47, 13.80)	10.16 (7.25, 14.36)	0.78
Lymphocyte, (10^9 /L)	1.09 (0.68, 1.56)	0.88 (0.69, 1.47)	0.42
CD3 ⁺ absolute lymphocyte, (/μL)	896.5 (626.5, 1349.5)	747 (549, 1210.75)	0.10
CD4 ⁺ absolute lymphocyte, (/μL)	554 (384, 866.25)	488 (331.5, 720.25)	0.057
CD8 ⁺ absolute lymphocyte, (/μL)	288.5 (202.75, 412.75)	247 (182.25, 386.5)	0.25
IgA, (mg/dl)	265 (213.5, 316.75)	251.5 (196.25, 320.25)	0.35
IgG, (mg/dl)	1185 (894, 1388.5)	1165 (901.5, 1340)	0.68

IgM, (mg/dl)	83 (58, 120.5)	82.5 (64, 112)	0.95
Procalcitonin, (µg/L)	0.21 (0.07, 1.16)	0.53 (0.1, 1.67)	0.047
Platelet, (10 ⁹ /L)	195 (130, 248)	204.5 (127, 305.25)	0.18
Albumin, (g/L)	29 (23.25, 34)	29 (24, 33)	0.45
ALT, (IU/L)	19.5 (14.25, 33.75)	22 (10, 42.75)	1.00
AST, (IU/L)	23 (16.25, 46.75)	25 (15.25, 54)	0.58
Scr, (umol/L)	73.5 (55, 122)	69.5 (55.25, 100.25)	0.44
BUN, (mmol/L)	7.1 (4.8,12)	6.7 (4.65, 12.7)	0.87
Pro-BNP, (pg/ml)	1013 (232, 3395)	656 (235, 2120)	0.18
Antibiotic therapy (n)			
Beta-lactams	73	84	0.424
Beta-lactamase inhibitors	24	29	0.637
Carbapenems	45	55	0.430
Macrolide	15	11	0.294
Quinolones	58	63	0.961
Glycopeptides	17	23	0.432
Aminoglycosides	6	6	0.878
Linezolid	17	21	0.671
Tigecycline	5	7	0.647
Azoles	7	6	0.655
Echinocandins	3	4	1.00
Outcome (n)			
Hospital length of stay, (days)	16 (9, 32)	17 (10,34)	0.726
28-day mortality, (n, %)	16	12	0.302

Abbreviations: IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; ALT, alanine aminotransferase; AST, aspartate transaminase; Scr, serum creatinine; BUN, blood urea nitrogen; pro-BNP, pro-brain natriuretic peptide

Comparison of the indicators between DM patients with severe CAP and non-severe CAP in prediction model group

As shown in Table 2, the diabetic patients who developed severe CAP showed higher levels of fasting plasma glucose and HbA1C as compared with non-severe CAP patients. Besides, of the patients with severe CAP, the incidences of comorbid respiratory and renal disease were increased than those in non-severe CAP patients.

Table 2. Comparison of the indicators between DM patients with severe CAP and non-severe CAP in the prediction model group.

Variables	Severe pneumonia (n=49)	Non-severe pneumonia (n=51)	<i>P</i> value
Age mean $\pm$ SD (yrs)	67.96 $\pm$ 1.81	67.35 $\pm$ 2.03	0.82
>65 yrs (%)	68 (62.39%)	55 (55.56%)	0.32
Male gender (n %)	35 (71.43%)	34(66.67%)	0.61
Smoking (n %)	14 (28.57)	19 (37.25)	0.36
Drinking (n %)	5 (10.20)	6 (11.76)	0.80
Fasting plasma glucose (mmol/L)	10.43 (8.81, 13.11)	9.04 (7.25, 11.72)	0.036
HbA1C (%)	8.5 (7.8,9.15)	7.4 (7.2,7.8)	<0.0001

Chronic diseases, (n, %)			
Chronic respiratory disease	2 (4.08%)	8 (15.69%)	0.053
Congestive heart failure	17 (34.69%)	12 (23.53%)	0.22
Hypertension	36 (73.47)	33 (64.71)	0.34
Kidney disease	15 (30.61%)	3 (5.88%)	0.001
History of stroke	12 (24.49%)	11 (21.57%)	0.73
Lab examinations			
C-reactive protein (mg/L)	79.1 (28.55,139.25)	22 (7.4,64)	<0.0001
White blood cell (10 ⁹ /L)	12.19 (8.67, 14.70)	8.94 (7.23, 11.52)	0.0031
Lymphocyte (10 ⁹ /L)	0.8 (0.56, 1.14)	1.4(0.95,1.91)	<0.0001
CD3 ⁺ absolute lymphocyte (/μL)	678 (489,911.5)	1259 (888,1588)	<0.0001
CD4 ⁺ absolute lymphocyte (/μL)	433 (286.5, 538)	799 (554, 1088)	<0.0001
CD8 ⁺ absolute lymphocyte (/μL)	234 (120.5,303.5)	390 (255, 531)	<0.0001
IgA (mg/dl)	234 (190,320)	284 (249, 298)	0.057
IgG (mg/dl)	980 (853, 1190)	1300 (1180,1476)	<0.0001
IgM (mg/dl)	66 (47.5,78.5)	108 (88,131)	<0.0001
Procalcitonin (μg/L)	0.7 (0.24,2.08)	0.09 (0.05,0.19)	<0.0001
Platelet (10 ⁹ /L)	151 (99,226)	216.5 (179.75,264.5)	0.0005
Albumin (g/L)	26 (21.5,31)	32 (27,37)	<0.0001
ALT (IU/L)	21 (14 ,37)	19 (15,31)	0.77
AST (IU/L)	35 (18.5,55)	20 (16, 31)	0.0055
Scr (umol/L)	97 (53.5,186.5)	70 (55,88)	0.037
BUN (mmol/L)	10.35 (7.025,15.05)	5.5 (3.8,7.8)	<0.0001
Pro-BNP (pg/ml)	2198 (606, 8698.5)	571.3 (92.625, 1476.75)	0.0001

Microbiological findings (n)			
Gram-positive	4	0	0.054
Gram-negative	5	2	0.264
Fungi	1	4	0.264
Virus	4	2	0.432
Unknown	38	44	0.256
Mixed	3	1	0.357

Abbreviations: IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; ALT, alanine aminotransferase; AST, aspartate transaminase; Scr, serum creatinine; BUN, blood urea nitrogen; pro-BNP, pro-brain natriuretic peptide

Compared to DM patients with non-severe CAP, severe CAP patients showed significantly higher values for the CRP, WBC, PCT, AST, Scr, BUN, and pro-BNP (Table 2) that DM patients with severe CAP may develop more complications.

Of note, the lymphocyte subsets counts were analyzed by the CAP severity (Table 3). DM patients with severe CAP had lower ALCs and lower CD3⁺, CD4⁺, and CD8⁺ T cell counts than those in non-severe CAP patients. In addition, DM patients with severe CAP showed significantly lower values for the IgM and IgG (Table 2). Serum immunoglobulin levels decreased in relation to the severity of CAP in DM patients.

Table 3. Univariate and multivariate logistic regression analysis of risk factors for progression to severe pneumonia among DM patients with CAP.

	Univariate logistic regression			Multivariate logistic regression	
Variables	OR (95% CI)	p value	Coefficient	OR (95% CI)	p value
C-reactive protein mg/L	1.013(1.005,1.020)	0.0001	0.013	1.018(1.003,1.033)	0.017
Kidney disease	8.82 (2.38, 32.67)	0.0002	2.177	4.438(0.152, 129.19)	0.386
Hypertension	1.51(0.64, 3.55)	0.343	0.412		
FBG	1.000(0.955, 1.047)	0.996	0.0001		
HbA1C	4.04(2.13, 7.67)	<0.0001	1.40	7.213(1.769, 20.41)	0.006
White blood cell 10 ³ /mm ³	1.13(1.02,1.24)	0.01	0.122	1.132(0.938,1.366)	0.197
lymphocyte	0.173(0.073,0.408)	<0.0001	-1.76	0.056(0.0067,0.471)	0.008
IgG (mg/dl)	0.999(0.997,1.000)	0.010	-0.0015	0.999 (0.997,1.002)	0.564
IgM (mg/dl)	0.979(0.968,0.991)	<0.0001	-0.021	0.974(0.951,0.998)	0.033
Procalcitonin µg/L	1.117(0.966,1.291)	0.017	0.111	1.343(0.936,1.928)	0.109
Platelet 10 ³ /mm ³	0.994(0.989,0.998)	0.005	-0.00628	0.995(0.987,1.004)	0.325
Albumin (g/L)	0.862(0.799,0.930)	<0.0001	-0.148	-	-
AST (IU/L)	1.032(1.010,1.054)	<0.0001	0.0316	0.892(0.768,1.036)	0.136
Scr (umol/L)	1.007(1.0015,1.0128)	0.0016	0.0070	1.022(0.979,1.067)	0.325
BUN (mmol/L)	1.174(1.067,1.291)	<0.0001	0.160	0.998(0.984,1.011)	0.728
Pro-BNP (pg/ml)	1.000 (1.000,1.000)	<0.0001	0.00032	0.995(0.967,1.025)	0.755

Abbreviations: FBG, fasting blood glucose; IgG, immunoglobulin G; IgM, immunoglobulin M; AST, aspartate transaminase; Scr, serum creatinine; BUN, blood urea nitrogen; pro-BNP, pro-brain natriuretic peptide

Analysis of the risk factors for progression to severe pneumonia in DM patients with pneumonia admitted

To determine early prediction factors of severe pneumonia development in DM patients with pneumonia admitted, we performed a univariate logistic

regression analysis. The results showed that CRP, kidney disease, HbA1C, ALC, IgM, IgG, PCT, PLT, albumin, AST, Scr, BUN, and pro-BNP might be used as predictive factors for severe pneumonia development in DM patients with pneumonia admitted.

To further determine the independent predictive factors for severe pneumonia development in DM patients, multivariate logistic regression analysis was performed. In multivariate analysis, CRP, HbA1C, ALC, and IgM were independently associated with severe CAP development in DM patients (Table 3).

Development of a prediction model and validating in the validation group

We developed a prediction model to determine the weight of independent prediction factors of severe pneumonia development in DM patients. The prediction model was established based on multivariate analysis: the prediction model = $0.0179555 * \text{CRP} + 1.975918 * \text{HbA1C} - 2.879364 * \text{ALC} - 0.026255 * \text{IgM} - 8.220555$.

The validation group was used to further validate the predictive accuracy of this model. Different threshold performances including sensitivity, specificity, positive predictive value and negative predictive value were shown in Table 4. The predictive accuracy value was determined by ROC curve analysis in the validation group. Figure 1 showed that the area under ROC (AUROC) curve in the validation group was 0.851 (0.781–0.921) with statistical significance

($P < .05$). The cutoff value was 2.155. The according sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the prediction model in the validation group was 76.7%, 77.1%, 80.1%, 72.6%, and 76.9%, respectively.

Table 4. Predicting value of the model for severe pneumonia among DM patients with CAP.

Cut-off	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
≥ 0	93.33	43.75	67.47	84.00
≥ 1	90.00	62.50	75.00	83.33
≥ 2	80.00	70.83	77.42	73.91
≥ 3	70.00	83.33	84.00	68.97
≥ 4	65.00	85.42	84.78	66.13
≥ 5	60.00	91.67	90.00	64.71
≥ 6	51.67	97.92	96.88	63.51
≥ 7	41.67	100.00	100.00	57.14

Discussion

As known, patients with diabetes are considered to have immunocompromised status and are more prone to have chronic organ dysfunction (such as cardiovascular and kidney function). Therefore, diabetic patients have a high risk of developing severe community-acquired pneumonia once diagnosed as community-acquired pneumonia. It is essential to identify these patients early and prevent them from progressing to SCAP to improve

clinical outcomes. However, there still lacks useful tools to predict the severity risk of the specific population until now. Therefore, a retrospective study was conducted to develop a tool for predicting severe CAP resulting from CAP among diabetic patients. Our findings suggested that CRP, HbA1C, ALC, and IgM on admission were independently associated with the progression to severe CAP among patients with diabetes and CAP during hospitalization. Furthermore, a combination of these parameters was evaluated and validated for the prediction of severe CAP among diabetic patients and showed high predictive accuracy.

Hyperglycemia is thought to be associated with the immune system and may have a significant effect on the development of SCAP. First, hyperglycemia could reduce the mobilization of polymorphonuclear leukocytes, phagocytic activity, and chemotaxis. Second, some studies found that $\text{HbA1c} < 8.0\%$ may aid to enhance CD4^+ T cell response to foreign antigens¹⁷. Third, in diabetic patients, glycation of immunoglobulin was correlated with an increased level of HbA1c, which would impair the biological function of antibodies¹⁸. In our study, fasting plasma glucose and HbA1C were significantly higher in the severe CAP group than the non-severe CAP group. HbA1C was confirmed an association with the progression of severe CAP by multivariate analysis. Whether hyperglycemia is associated with the mortality and severity of CAP remained unclear. A study conducted by Schuetz et al. evaluated the role of

hyperglycemia in CAP patients¹⁹. The results suggested that in the non-critical-care setting, initial hyperglycemia was associated with a significant inflammatory response in non-diabetic patients with CAP. However, the association between hyperglycemia at admission and outcome was not found in the diabetic population. It is worthy of being noted that in the diabetic population, persistent hyperglycemia (over 96 h after admission) was associated with adverse clinical outcomes and abnormal levels of CRP. Moreover, patients with diabetes are commonly comorbid with chronic complications (such as cardiovascular disease, renal failure, and pulmonary microangiopathy), which may also influence the progression of CAP and prognosis⁷. Similarly, a higher proportion of chronic respiratory diseases and kidney diseases were found in severe CAP patients. Moreover, compared with non-severe CAP patients, severe CAP patients have higher levels of CRP, PCT, Scr, BUN, AST, pro-BNP, and lower levels of platelet and albumin, which reflect that severe complications are common in patients with diabetes and severe CAP.

Usually, CAP occurs when the immune system is compromised and encounters a microbial infection. Several variables associated with the immune system have been demonstrated as risk factors of CAP or biomarkers of CAP severity. First, lymphocytes are crucial for immunity. In hospitalized CAP patients, lymphopenia was found as a risk factor of mortality, and lymphocyte count could improve the prediction accuracy of the CURB-65 score for 30-day

mortality²⁰. In a study by Bermejo-Martin et al., the association between neutrophil (or lymphocyte) count and 30-day mortality was assessed in hospitalized CAP patients, and the results suggested that patients with lymphocytes $<724/\text{mm}^3$ had increased mortality by 1.93-fold, irrespective of the CURB-65 score, critical illness, and appropriate antibiotic treatment²⁰. Second, complement factors have been investigated in patients with diabetes. It was reported that compared with patients without diabetes, patients with diabetes have a lower level of C4, which proved to be associated with dysfunction of neutrophils and decreased response to cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-gamma (IFN- γ), and tumor necrosis factor (TNF- α)²¹. Third, humoral immunity is also essential for the prevention and control of respiratory infections. Impaired humoral immunity would lead to an increased risk for CAP. Torre et al. measured serum total IgG (IgG subclasses, such as IgG1, IgG2, IgG3, and IgG4), IgA, and IgM in CAP patients at the first hospital admission, and the authors found that serum immunoglobulin levels were positively correlated with the severity of CAP and low levels of IgG (or subclasses) were associated with ICU admission and 30-day mortality^{22,23}. Our findings are consistent with these previous studies. In the cohort of patients with diabetes, we found that, compared with non-severe CAP patients, severe CAP patients have lower levels of ALC, CD3⁺ T cell, CD4⁺ T cell, CD8⁺ T cell, IgA, IgM, and IgG. In addition, the progression of CAP to

severe CAP was associated with ALC and IgM. In general, it is thought that innate and adaptive immune response may be correlated with the severity of CAP in patients with diabetes, and immunological profiling could provide a valuable tool for severity assessment and prognosis evaluation of CAP among patients with diabetes.

It is vital to develop a prediction tool for early identification of progression to severe pneumonia. In this study, selected combined biomarkers, including CRP, HbA1C, ALC, and IgM, showed a good predictive value of severe CAP among patients with diabetes and CAP. These biomarkers represented an association of severe CAP with inflammatory (CRP), immune status (ALC, IgM), and specific comorbidity factors (HbA1C). Until now, several predictive tools have been characterized in the management of pneumonia. ICU admission is one index that reflects the progression of pneumonia. PSI score has been evaluated in the prediction of hospital/ICU admission. However, the result showed that the PSI perform less well with an AUROC of 0.56–0.85²⁴. As known, IDSA/ATS has developed new criteria to identify patients with a high risk of ICU admission¹⁵. Besides the major criteria mentioned in the guidelines, minor criteria were also suggested for the predictive role. Moreover, in a recent meta-analysis, the prognostic role of minor criteria for ICU admission has been improved, validated, and confirmed²⁵. Also, Kolditz et al. found that the first six minor criteria (without white cell count

<4000 cells/mm³, platelets <100 000 cells/mm³, and hypothermia <36°C) with a combination of hypothermia could predict the death within 7-days²⁶. According to the results²⁶, the minor criteria appear to have excellent negative predictive values for emergency CAP; however, positive predictive values remained very low. Similarly, Renaud et al. evaluated risk factors of ICU admission (within 72 h) in patients with pneumonia and found that hyponatremia, hyperglycemia, leucopenia, and pleural effusion were associated with ICU admission^{27,28}. To assess CAP's outcome, physicians have evaluated several tools for predicting mortality among high-risk patients. For example, CURB-65 shows a good discriminatory power (AUROC 0.73–0.87) to predict mortality and perform less for predicting ICU admission (0.60–0.78)²⁴. Another study found several risk factors, such as altered mental status, multi-lobar pneumonia and systemic hypotension, age, pneumococcal bacteremia, and discordant empirical antibiotic therapy, have an independent association with mortality within 48 h admission to hospital²⁹.

Of note, we found that a total of 72.1% of patients were diagnosed with pneumonia without definite microbiological etiology in our study (see Figure S1), which is consistent with other studies. The most common etiologies for CAP in DM patients were *Klebsiella pneumoniae* (6.3%), *Staphylococcus aureus* (3.8%), cytomegalovirus (3.8%), *Mycoplasma pneumoniae* (3.4%), and influenza virus A (2.9%). We also found that patients with *Staphylococcus*

aureus or cytomegalovirus more likely progressed to SCAP during the hospital stay. However, we did not include these two pathogens in multivariate analysis for the small sample of microbiological data.

Although several interesting findings were found, our study remains to have several limitations. First, due to the study's retrospective nature, selection bias may exist, and risk for confounding factors may be indicated. Second, the sample size was relatively small, and further analysis may be required to examine the validity of our findings. Third, we found that more patients with *Staphylococcus aureus* or cytomegalovirus progressed to severe CAP during hospitalization than those without. However, no significant difference could be found in prediction model group due to the small sample size. Thus, in our further study, we would enroll microbiological etiological data to see if this could predict the progression to SCAP in diabetic patients.

Conclusion

Our study found that in patients with diabetes and CAP, HbA1C, CRP, ALC, IgM at admission, and their combination could be used to predict the progression to severe CAP during hospitalization with good accuracy. Due to the included biomarkers are common, our finding may be performed well in

clinical practice and then improve the early management of diabetic patients with CAP.

Conflict of Interest

The authors declare no conflict of interest.

Funding Source

This study was supported by the National Key R&D Program of China (2017YFC1309700, 2017YFC1309705), National Natural Science Foundation of China (81772040, 81770005, 81801885), Shanghai Sailing Program (18YF1413800), Guangci Excellent Youth Training Program of Ruijin Hospital (GCQN-2019-B14) and Emergency science and technology projects of Shanghai Science and Technology Commission (No. 20411950300/20411950301).

Ethical Approval

The study protocol was approved by the Ruijin Hospital Ethics Committee, Shanghai Jiaotong University School of Medicine, China. Informed consent from study patients was not required because of the retrospective design of the cohort study.

References

1. Cheng LJ, Chen JH, Lin MY, et al. A competing risk analysis of sequential complication development in Asian type 2 diabetes mellitus patients. *Sci Rep* 2015;5:15687.
2. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. *N Engl J Med* 1999; 341: 1906-1912.
3. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in Hospitalizations for Pneumonia Among Persons Aged 65 Years or Older in the United States, 1988-2002. *JAMA* 2005 Dec 7;294(21):2712-9.
4. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. *Diabetes Care* 2003; 26: 510-513.
5. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management, and relationship to glycaemic control. *Diabetes Metab Res Rev* 2007; 23: 3-13.
6. Thomsen RW, Mor A. Diabetes and risk of community-acquired respiratory tract infections, urinary tract infections, and bacteremia. *The Open Infectious Diseases Journal* 2012; 6(Suppl 1: M2): 27-39.
7. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. *Pneumonia. Infect Dis Clin North Am* 1995; 9:65-96.

8. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicenter cohort studies. *Thorax* 2010; 65: 870-877.
9. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis* 2005; 41: 281-288.
10. López-de-Andrés A, de Miguel-Díez J, Jiménez-Trujillo I, et al. Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. *BMJ Open* 2017; 7: e013097.
11. MacIntyre EJ, Majumdar SR, Gamble JM, et al. Stress Hyperglycemia and Newly Diagnosed Diabetes in 2124 Patients Hospitalized with Pneumonia. *The American Journal of Medicine* 2012; 125: 1036.e17-1036.e23.
12. Kornum JB, Thomsen RW, Riis A, et al. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. *Diabetes Care* 2007; 30: 2251-2257.
13. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. *Intensive Care Med* 2014; 40: 973-980.
14. Falguera M, Pifarre R, Martin A, et al. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. *Chest J* 2005; 128: 3233-3239.

15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44 Suppl 2: S27-72.
16. Méndez R, Menéndez R, Amara-Elori I, et al. Lymphopenic community-acquired pneumonia is associated to dysregulated immune response, increased severity, and mortality. *J Infect* 2019; 78(6): 423-431.
17. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab* 2012; 16: 27-36.
18. Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. *Pneumonol Alergol Pol* 2015; 83: 401-408.
19. Schuetz P, Friedli N, Grolimund E, et al. Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study. *Diabetologia* 2014; 57: 275-284.
20. Bermejo-Martin JF, Cilloniz C, Mendez R, et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. *EBioMedicine* 2017; 24: 231 – 36.
21. Price CL, Al Hassi HO, English NR, et al. Methylglyoxal modulates immune responses: relevance to diabetes. *J Cell Mol Med* 2010; 14: 1806-1815.

22. de la Torre Mari C, Palomera Elisabet, Serra-Prat Mateu, et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. *Journal of Critical Care* 2016; 35:115-9.
23. de la Torre MC, Torán P, Serra-Prat M, et al. Serum levels of immunoglobulins and severity of community-acquired pneumonia. *BMJ Open Resp Res* 2016; 3: e000152.
24. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. *Intensive Care Med* 2011; 37: 1409-1420.
25. Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. *Eur Respir J* 2014; 43: 842-51.
26. Kolditz M, Ewig S, Klapdor B, et al. Community-acquired pneumonia as medical emergency: predictors of early deterioration. *Thorax* 2015; 70: 551-8.
27. Renaud B, Labarere J, Coma E, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. *Crit Care* 2009; 13: R54.
28. Labarere J, Schuetz P, Renaud B, et al. Validation of a clinical prediction model for early admission to the intensive care unit of patients with pneumonia. *Acad Emerg Med* 2012; 19: 993-1003.

29. Garcia-Vidal C, Fernandez-Sabe N, Carratala J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. *Eur Respir J* 2008; 32: 733-9.

Figure Legends

Figure 1. ROC curve analysis of model to predict the progression of CAP among DM patients.

Figure S1. Microbiological findings of CAP patients with DM.